Topics

CytoSen Therapeutics, Inc. Company Profile

00:35 EST 13th December 2019 | BioPortfolio

CytoSen is a private biopharmaceutical company on the front line of advancing clinical development of next generation NK cells with the first scalable, therapeutic platform for high dose, cancer-killing NK cells calibrated to each cancer target while reinforcing immune defenses.


News Articles [844 Associated News Articles listed on BioPortfolio]

Kiadis acquires CytoSen Therapeutics

Kiadis Pharma Netherlands BV agreed to issue 1.94mm of its common shares (valued at $18.7mm based on the 10-day market average) to acquire privately held cell therapy firm CytoSen Therapeutics Inc.

Kiadis to Restructure Months After Acquiring CytoSen Therapeutics

The company will discontinue development of its lead T-cell asset, ATIR101, halt its ongoing Phase III trial and lay off half its staff.

Kiadis raises €28mm in latest private placement

Kiadis Pharma Netherlands BV (developing treatments for blood cancers) raised €28mm ($30.8mm) through a private placement of 3.7mm new shares at €7.50 (a 10% discount). Funds will help the firm ad...

Kiadis Pharma's Extraordinary General Meeting of Shareholders Approves CytoSen Acquisition

Amsterdam, The Netherlands, May 29, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharm...

CRISPR Therapeutics Takes Over Joint Venture Casebia Therapeutics from Bayer

LEVERKUSEN, Germany and ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 21, 2019 /PRNewswire/ — CRISPR Therapeutics and Bayer today announced proposed plans whereby Casebia Therapeutics, a joint ven...

Proteon Therapeutics to merge with ArTara Therapeutics

Proteon Therapeutics, which focuses on kidney and vascular diseases, has signed a definitive agreement to merge with rare and speciality...Read More... The post Proteon Therapeutics to merge with ArTa...

Clover Therapeutics Launches With Eye on Age-Related Ocular Diseases

Clover Therapeutics, which sprung out of Clover Health, is supported by a number of biotech and pharma veterans, including Pfizer veteran Cheng Zhang, who is heading up therapeutics, and Genentech vet...

DGAP-Stimmrechte: Vivoryon Therapeutics AG (deutsch)

Vivoryon Therapeutics AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung DGAP Stimmrechtsmitteilung: Vivoryon Therapeutics AG Vivoryon Therapeutics AG: Veröffen...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [438 Associated PubMed Articles listed on BioPortfolio]

Digital Therapeutics: Emerging New Therapy for Neurologic Deficits after Stroke.

Digital therapeutics is an evidence-based intervention using high-quality software, with the sole purpose of treatment. As many healthcare systems are encountering high demands of quality outcomes, th...

Measurement of mRNA therapeutics: method development and validation challenges.

The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for t...

Pharmacovigilance 2030: Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and Therapeutics.

From Engineered Tissues and Microfludics to Human Eyes-On-A-Chip.

Antiglaucoma EP Agonists: A Long Road That Led Somewhere.

For >2 decades, EP agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first...

Clinical Trials [200 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1400 Associated Companies listed on BioPortfolio]

CytoSen Therapeutics, Inc.

CytoSen is a private biopharmaceutical company on the front line of advancing clinical development of next generation NK cells with the first scalable, therapeutic platform for hi...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "CytoSen Therapeutics, Inc." on BioPortfolio

We have published hundreds of CytoSen Therapeutics, Inc. news stories on BioPortfolio along with dozens of CytoSen Therapeutics, Inc. Clinical Trials and PubMed Articles about CytoSen Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CytoSen Therapeutics, Inc. Companies in our database. You can also find out about relevant CytoSen Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record